The agent, an anti-C5 antibody that blocks formation of the MAC and C5a generation, has been shown to reduce thromboembolic events in patients with PNH [94] and aHUS [95]. This evidence concerns the gene C5 and paroxysmal nocturnal hemoglobinuria.